REG - Allergy Therapeutics - Grant of Options under Long Term Incentive Scheme

Allergy TherapeuticsAnnouncement

28/01/2026 17:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260128:nRSb7908Qa&default-theme=true

RNS Number : 7908Q  Allergy Therapeutics PLC  28 January 2026

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company" or the "Group")

 

Grant of Options under Long Term Incentive Scheme

 

28 January 2026: Allergy Therapeutics plc (AIM: AGY), the fully integrated
commercial biotechnology company specialising in allergy immunotherapies,
today announces that on 27 January 2026 it granted share option awards to key
members of Allergy Therapeutics' management team including certain of its
persons discharging managerial responsibilities ("PDMRS").

 

The Board has granted options to encourage long-term value creation for the
Company's shareholders, and so that the individuals identified as key people
to lead the business into the future are appropriately incentivised in a
manner that aligns with the interests of the Group's stakeholders.

 

Vesting is conditional on the satisfaction of performance criteria over a
three-year period. Vesting of 70 per cent. of the award subject to Adjusted
EBITDA* performance and vesting of the remaining 30 per cent. of the award is
subject to share price performance.

 

The following awards have been made in accordance with the Group LTIP:

 

 Name           Title                    Number of share options granted  Resultant                      Performance period              Vesting Date  Exercise price  Number of

                                                                          number of share options held                                                                 Ordinary Shares

                                                                                                                                                                       held
 Manuel Llobet  Chief Executive Officer  5,409,724                        142,578,024                    3 years commencing 1 July 2025  30 June 2028  £0.001          5,001,200
 Shaun Furlong  Chief Financial Officer  2,489,627                        21,704,724                     3 years commencing 1 July 2025  30 June 2028  £0.001          1,507

 

The number of Ordinary Shares stated above is the maximum number that could be
issued to each PDMR upon full satisfaction of the performance conditions
attached to the awards.

 

The Group's Remuneration Committee will review the performance conditions at
periodic intervals to ensure they remain appropriate. As a result of any such
review, the Committee will retain discretion to amend the conditions where
appropriate having regard to overall Company performance and wider stakeholder
experience.

 

Following the above grants of options, the Company has options outstanding
over 365,205,852 ordinary shares, representing 5.95% of the Company's current
issued share capital.

 

This announcement contains inside information for the purposes of the retained
UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR").

 

*Adjusted EBITDA means earnings before interest, taxes, depreciation and
amortisation adjusted to exclude the impact of R&D expenditure,
exceptional items, equity settled long term incentive plans and gains or
losses arising on fundraising activities. The Committee may, in its absolute
discretion, make further adjustments to the Adjusted EBITDA figure disclosed
in the Company's audited consolidated accounts for the relevant financial
year, so that the Adjusted EBITDA figure fairly reflects underlying Group
financial performance. Adjustments may include, but are not limited to, the
cost of long-term strategic investments, approved after the relevant
performance condition was set, with a short-term negative impact on Adjusted
EBITDA in the relevant financial year. Such adjustments will be applied on a
logical, transparent and consistent basis.

 

-  ENDS -

For further information, please contact:

 

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

+44 (0)1903 845 820

 

Cavendish Capital Markets Limited (Nominated Adviser and Broker)

Geoff Nash/Giles Balleny/Seamus Fricker

Nigel Birks - Life Science Specialist Sales

+44 (0)20 7220 0500

 

ICR Healthcare

Mary-Jane Elliott/David Daley/Davide Salvi

+44 (0)20 3709 5700

allergytherapeutics@icrhealthcare.com
(mailto:allergytherapeutics@icrhealthcare.com)

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international commercial biotechnology company,
headquartered in the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapies that have the potential to
cure disease. The Group sells proprietary and third-party products from its
subsidiaries and branches in nine major European countries and via
distribution agreements in an additional four countries. For more information,
please see www.allergytherapeutics.com (http://www.allergytherapeutics.com) .

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them in
accordance with the Market Abuse Regulations

 

 1   Details of the persons discharging managerial responsibilities / person
     closely associated
 a)  Name                                                         Manuel Llobet
 2   Reason for the notification
 a)  Position/status                                              Chief Executive Officer
 b)  Initial notification /Amendment                              Initial notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Allergy Therapeutics plc
 b)  LEI                                                          213800PQ7AHK7KGVOE23
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary shares of 0.1 pence each

     Identification code                                          GB00B02LCQ05
 b)  Nature of the transaction                                    Grant of options
 c)  Price(s) and volume(s)                                       Exercise Price per share  Volume
                                                                                            5,409,724

                                                                  £0.001

 d)  Aggregated information                                       See 4c) above

     - Aggregated volume

     - Price
 e)  Date of the transaction                                      27 January 2026
 f)  Place of the transaction                                     Outside a trading venue

d)

Aggregated information

- Aggregated volume

- Price

See 4c) above

e)

Date of the transaction

27 January 2026

f)

Place of the transaction

Outside a trading venue

 

 

 1   Details of the persons discharging managerial responsibilities / person
     closely associated
 a)  Name                                                         Shaun Furlong
 2   Reason for the notification
 a)  Position/status                                              Chief Financial Officer
 b)  Initial notification /Amendment                              Initial notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Allergy Therapeutics plc
 b)  LEI                                                          213800PQ7AHK7KGVOE23
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary shares of 0.1 pence each

     Identification code                                          GB00B02LCQ05
 b)  Nature of the transaction                                    Grant of options
 c)  Price(s) and volume(s)                                       Exercise Price per share  Volume

                                                                  £0.001                    2,489,627
 d)  Aggregated information                                       See 4c) above

     - Aggregated volume

     - Price
 e)  Date of the transaction                                      27 January 2026
 f)  Place of the transaction                                     Outside a trading venue

d)

Aggregated information

- Aggregated volume

- Price

See 4c) above

e)

Date of the transaction

27 January 2026

f)

Place of the transaction

Outside a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBPMFTMTITBFF



            Copyright 2019 Regulatory News Service, all rights reserved